Method for molecular diagnosis of tumor angiogenesis and metasta

Details Method for molecular diagnosis of tumor angiogenesis and metasta Method for molecular diagnosis of tumor angiogenesis and metasta

1996-03-21

1999-08-24

Degen, Nancy

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

435 6, 435 71, 435 792, 435 912, 435366, 536 231, C12Q 100, G01N 3353, C12N 508, C07H 2104

Patent

active

059423854

ABSTRACT:
The invention is directed to methods of assessing the molecular stage of an disease characterized by abnormal angiogenesis. More particularly, the invention is directed to a method of determining the metastatic potential of a tumor by determining the presence of specific molecular markers. The invention is based in part on the discovery that the key marker for determining the eventual metastasis of a tumor is vascular endothelia growth factor. Knowledge of the particular markers present in a tumor condition allows the physician to tailor cancer treatment and manage the disease condition.

REFERENCES:
patent: 4376110 (1983-03-01), David et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4946778 (1990-08-01), Ladner et al.
Aiello, L. P. et al. (Nov. 1995). Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. USA 92, 10457-10461.
Asano, M. et al. (Nov. 1995). Inhibitor of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Cancer Research 55, 5296-5301.
Baker, P. N., Kransnow, J., Roberts, J.M., and Yeo, K.-T. (Nov. 1995). Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia. Obstetrics & Gynecology 86, 815-821.
Berger, D.P., Herbstritt, L., Dengler, W. A., Marme, D., Mertelsmann, R., and Fiebig, H. H. (Oct. 1995). Vascular endothelial growth factor (VEGF) mRNA expression in human tumor models of different histologies. Annals of Oncology 6, 817-825.
Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S.-M., Lee, T., Pope, S. G., Riordan, G. S., and Whitlow, M. (1988). Single-chain antigen-binding proteins. Science 242, 423-426.
Bishop, J. M. (1991). Molecular themes in oncogenesis. Cell 64, 235-248.
Butler, J. E. (1981). The amplified ELISA: principles of and applications for the comparative quantitation of class and subclass antibodies and the distribution of antibodies and antigens in biochemical separates. Methods in Enzymology 73, 482-523.
Claffey, K. P. et al. (Jan. 1996). Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Research 56, 172-181.
Cole, S. P. C., Kozbor, D., and Roder, J. C. (1985). The EBV-Hybridoma technique and its application to human lung cancer. Monoclonal Antibodies and Cancer Therapy, 77-96.
Cote, R. J., Morrissey, D. M., Houghton, A. N., Beattie, E. J. J., Oettgen, H. F., and Old, L. J. (1983). Generation of human monoclonal antibodies reactive with cellular antigens. Proc. Natl. Acad. Sci. USA 80, 2026-2030.
Ferrara, N. (1995). The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Research and Treatment 36(2), 127-137.
Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82, 4-6.
Folkman, J., and Shing, Y. (1992). Angiogenesis. The Journal of Biological Chemistry 267, 10931-10934.
Geursen, A. et al. (1993). Population study of T cell receptor Vb gene usage in peripheral blood lymphocytes: differences in ethnic groups. Clin. Exp Immunol. 94, 201-207.
Greenspan, N. S., and Bona, C. A. (1993). Idiotypes: structure and immunogenicity. The FASEB Journal 7, 437-444.
Houck, K. A. et al. (1991). The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Molecular Endocrinology 5, 1806-1814.
Huse, W. D., Sastry, L., Iverson, S. A., Kang, A. S., Alting-Mees, M., Burton, D. R., Benkovic, S. J., and Lerner, R. A. (1989). Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246, 1275-1281.
Huston, J. S. et al. (1988). Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA 85, 5879-5883.
Kendall, R. L., and Thomas, K. A. (1993). Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. 90, 10705-10709.
Klagsbrun, M., and Soker, S. (1993). VEGF/VPF: the angiogenesis factor found? Current Biology 3, 699-702.
Kondo, S. et al. (1993). Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Bioechemical and Biophysical Research Communications 194, 1234-1241.
Kozbor, D., and Roder, J. C. (1983). The production of monoclonal antibodies from human lymphocytes. Immunology Today 4, 72-79.
Kohler, G., and Milstein, C. (1975). Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 256, 495-497.
Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. (1991). Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64, 327-336.
Matthews, W. et al. (1991). A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc. Natl. Acad. Sci. USA 88, 9026-9030.
Millauer, B., Shawver, L. K., Plate, K. H., Risau, W., and Ullrich, A. (1994). Glioblatoma growth inhibited in vivo by a dominant-negative FLK-1 mutant. Nature 367, 576-579.
Morrison, S. L., Johnson, M. J., Herzenberg, L. A., and Oi, V. T. (1984). Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA 81, 6851-6855.
Mustonen, T., and Alitalo, K. (May 1995). Endothelial receptor tyrosine kinases involved in angiogenesis. Journal of Cell Biology 129, 895-898.
Neuberger, M. S., Williams, G. T., and Fox, R. O. (1984). Recombinant antibodies possessing novel effector functions. Nature 312, 604-608.
Nisonoff, A. (1991). Idiotypes: concepts and applications. Journal of Immunology 147, 2429-2438.
Plate, K. H., Breier, G., Millauer, B., Ullrich, A., and Risau, W. (1993). Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Research 53, 5822-5827.
Schnurch, H., and Risau, W. (1993). Expression of tie-2, a member of a novel family of receptor tyrosine kinases, in the endothelial cell lineage. Development 119, 957-968.
Shibuya, M., Yamaguchi, S., Yamane, A., Ikeda, T., Tojo, A., Matsushime, H., and Sato, M. (1990). Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 5, 519-524.
Slamon, D. J. et al. (1989). Studies of the HER-2
eu Proto-oncogene in Human Breast and Ovarian Cancer. Science 244, 707-712.
Takahasi, Y. et al. (Sep. 1995). Expression of vascular endothelial growth fator and its receptor KDR correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Research 55, 3964-3968.
Takeda, S.-i., Naito, T., Hama, K., Noma, T., and Honjo, T. (1985). Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences. Nature 314, 452-454.
Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. (1991). The human gene for vascular endothelial growth factor. Journal of Biological Chemistry 266, 11947-11954.
Voller, A., Bartlett, A., and Bidwell, D. E. (1978). Enzyme immunoassays with special reference to ELISA techniques. Journal of Clinical Pathology 31, 507-520.
Wang, G. L., Jiang, B.-H., Rue, E. A., and Semenza, G. L. (Jun. 1995). Hypoxia-inducible factor 1 is a basic-helix-loop-helix-pas heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514.
Ward, E. S., Gussow, D., Griffiths, A. D., Jones, P. T., and Winter, G. (1989). Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341, 544-546.
Weidner, N., Semple, J. P., Welch,

Affiliated with

Also associated with

Rating

Method for molecular diagnosis of tumor angiogenesis and metasta does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for molecular diagnosis of tumor angiogenesis and metasta, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for molecular diagnosis of tumor angiogenesis and metasta will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-465453